Story perspectives

Russia Unveils Promising mRNA Cancer Vaccine EnteroMix

9/11/2025

45 10

Summary

Story summary

Russia has launched EnteroMix, an mRNA-based cancer vaccine showing promise in early trials, especially for colorectal cancer.
The vaccine appears to shrink tumors and slow growth without severe side effects, claiming 100% efficacy in preclinical trials.
Developed by the National Medical Research Radiology Centre and Engelhardt Institute, EnteroMix is tailored to each patient's RNA.
Clinical trials began in June 2025 with 48 volunteers; results are encouraging but need regulatory approval.
Experts advise caution due to the small sample size and absence of peer-reviewed data.

1 of 1

Story summary

Russia has launched EnteroMix, an mRNA-based cancer vaccine showing promise in early trials, especially for colorectal cancer.
The vaccine appears to shrink tumors and slow growth without severe side effects, claiming 100% efficacy in preclinical trials.
Developed by the National Medical Research Radiology Centre and Engelhardt Institute, EnteroMix is tailored to each patient's RNA.
Clinical trials began in June 2025 with 48 volunteers; results are encouraging but need regulatory approval.
Experts advise caution due to the small sample size and absence of peer-reviewed data.